To develop individual therapies for patients with breast cancers, the expression levels of ER, progesterone receptor (PgR), and human epidermal growth factor receptor 2 (HER2) in tumor specimens are currently evaluated using immunohistochemistry. Here, ERBB2 is linked to neoplasm.